Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation.

Autor: Clermont AC; KalVista Pharmaceuticals, Cambridge, United Kingdom., Murugesan N; KalVista Pharmaceuticals, Cambridge, United Kingdom., Edwards HJ; KalVista Pharmaceuticals, Cambridge, United Kingdom., Lee DK; KalVista Pharmaceuticals, Cambridge, United Kingdom., Bayliss NP; KalVista Pharmaceuticals, Cambridge, United Kingdom., Duckworth EJ; KalVista Pharmaceuticals, Cambridge, United Kingdom., Pethen SJ; KalVista Pharmaceuticals, Cambridge, United Kingdom., Hampton SL; KalVista Pharmaceuticals, Cambridge, United Kingdom., Gailani D; Hematology/Oncology Division, Vanderbilt University, Nashville, TN, United States., Feener EP; KalVista Pharmaceuticals, Cambridge, United Kingdom.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2023 Dec 19; Vol. 14, pp. 1287487. Date of Electronic Publication: 2023 Dec 19 (Print Publication: 2023).